Brian M. Slomovitz, MD, on dMMR Advanced or Recurrent Endometrial Cancer: KEYNOTE-C93/GOG-3064/ENGOT-en15
ESMO Congress 2026Advertisement
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, discusses results from a phase III, randomized, open-label study of first-line pembrolizumab vs carboplatin/paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial carcinoma (Abstract LBA12).
